Cynata Therapeutics

Products & Pipeline

Gain a direct line to Cynata Therapeutics leadership

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Contact Us

Pre-Clinical Development

Clinical Development

Scientific Publications

Intellectual Property

Cymerus™ Platform

Our technology

Company FAQs

Corporate Governance

Board of Directors

Management team

Scientific Advisory Board

About us

Analyst Research

Investor FAQs

Financial Reports

Right to Receive Documents

Investor Presentations

Share Price

Announcements

Investors

Updates

Home

Frank Ruhl Libre

Cynata is advancing a diverse pipeline of innovative cell therapies based on our proprietary Cymerus™ technology platform. Our clinical-stage programs span multiple therapeutic areas with significant unmet medical needs, positioning us at the forefront of regenerative medicine.

Our development portfolio includes several active clinical trials across various stages, providing multiple opportunities for value creation and potential commercial partnerships. With completed trials demonstrating promising safety and efficacy data, and ongoing studies progressing toward important milestones, Cynata is building a strong foundation of clinical evidence for our iPSC-derived mesenchymal stem cell therapies.

Currently, we are advancing four key programs that highlight the versatility and broad therapeutic potential of our Cymerus™ platform. Two of these programs are managed and funded directly by Cynata, while two are being managed by academic partners, and funded by grants. Importantly, Cynata retains commercial rights to all of these programs.

Our most advanced in-house program is a global Phase 2 clinical trial in acute graft-versus-host disease (aGvHD), which is actively recruiting patients following the success of our groundbreaking Phase 1 trial. We have also recently completed our Phase 1 clinical trial in diabetic foot ulcer (DFU) with positive results. Concurrently, we have completed recruitment in our Phase 3 clinical trial for osteoarthritis in partnership with the University of Sydney, with patients now in the follow-up phase. In partnership with Leiden University Medical Center in the Netherlands, our Phase 1/2 clinical trial in kidney transplantation continues to enrol patients. 

Beyond our clinical programs, Cynata has demonstrated the therapeutic potential of Cymerus™ MSCs in multiple preclinical models of major diseases. Our research has shown promising results in respiratory conditions, with studies in asthma and idiopathic pulmonary fibrosis revealing significant anti-inflammatory and anti-fibrotic effects. In cardiovascular applications, our preclinical work in heart attack (myocardial infarction), coronary artery disease, and critical limb ischemia has demonstrated the cells' ability to promote tissue repair and improve blood flow to damaged areas. We've also explored the immunomodulatory properties of our MSCs in sepsis models, where they have shown potential to reduce the harmful inflammatory cascade that leads to organ failure. Additionally, our preliminary investigations in brain cancer suggest MSCs may serve as targeted delivery vehicles for anti-cancer therapies, leveraging their natural ability to migrate to sites of inflammation and tumor growth.

Each of these programs represents a significant opportunity to address serious conditions where current treatment options are limited, with several near-term catalysts expected to drive our progress forward.

Explore clinical pipeline

Explore pre-clinical pipeline